Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 173 | 15,191 | 30% |
| 2020 | 192 | 17,005 | 33% |
| 2021 |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 13% of the cases CMS names in Illinois; 150 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
CGM & insulin pump management in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Ohio
| 2025 est. |
| ≈ 47,500 |
| – |
| 2026 est. | ≈ 52,100 | – |
| 231 |
| 24,112 |
| 37% |
| 2022 | 235 | 28,354 | 42% |
| 2023 | 278 | 34,825 | 45% |
| 2024 | 293 | 40,924 | 47% |
| 2025 from claims | – | 47,495 43,588–50,250 | 48% |
| 2026 forecast | – | 52,132 45,868–60,158 | 48% |
| 2027 forecast | – | 56,735 48,503–67,611 | 48% |
| 2028 forecast | – | 61,739 51,515–75,597 | 49% |
| 2029 forecast | – | 67,175 54,867–84,244 | 50% |
| 2030 forecast | – | 73,082 58,549–93,654 | 50% |
In 2025, 24% hospital outpatient, 76% office. The share outside the hospital has moved −10 pts since 2019.
| +22%/yr |
| 31.9 |
| 89% |
| 37,600 in 2030+8.6%/yr |
| Michigan | 215 | 22,586+13%/yr | +13%/yr | 26.2 | 68% | 36,200 in 2030+8.2%/yr |
| Missouri | 161 | 21,566+29%/yr | +29%/yr | 34.1 | 80% | 38,800 in 2030+10%/yr |
| Kansas | 76 | 13,034+33%/yr | +33%/yr | 31.9 | 84% | 23,200 in 2030+10%/yr |
| Wisconsin | 144 | 12,963+33%/yr | +33%/yr | 22.5 | 71% | 25,100 in 2030+12%/yr |
| Minnesota | 116 | 12,114+19%/yr | +19%/yr | 26.2 | 80% | 25,600 in 2030+13%/yr |
| Iowa | 54 | 9,706+30%/yr | +30%/yr | 21.6 | 65% | 17,100 in 2030+9.9%/yr |
| Nebraska | 54 | 8,132+36%/yr | +36%/yr | 30.9 | 76% | 14,300 in 2030+9.9%/yr |
| South Dakota | 26 | 3,993+45%/yr | +45%/yr | 30.4 | 9% | 7,150 in 2030+10%/yr |
| North Dakota | 12 | 1,926+24%/yr | +24%/yr | 19.1 | 48% | 3,400 in 2030+9.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Insulet leads with 34% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 10 companies reported engagement with Illinois’s surgeons worth $440K in consulting, speaking, meals and travel tied to these products, about $1,502 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.